Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Pioglitazone418 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00004 | 35258780 | Chin J Integr Med | Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00027 | 35250889 | Front Endocrinol (Lausanne) | Corrigendum: Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. | 2022 | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | 2022 | Details |
| A00162 | 35203687 | Biomedicines | A Novel 2-Hit Zebrafish Model to Study Early Pathogenesis of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00446 | 35080048 | J Gastroenterol Hepatol | Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. | 2022 | Details |
| A00459 | 35072848 | Inflammopharmacology | The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A00616 | 35027111 | J Am Coll Cardiol | Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. | 2022 | Details |
| A00651 | 35014161 | Diabetes Obes Metab | The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. | 2022 | Details |
| A00653 | 35014145 | Diabetes Obes Metab | Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). | 2022 | Details |
| A00656 | 35013417 | Sci Rep | Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver. | 2022 | Details |
| A01118 | 34863942 | Mol Metab | The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease. | 2021 | Details |
| A01137 | 34858740 | Cureus | Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes. | 2021 | Details |
| A01147 | 34855339 | FP Essent | Liver Disease: Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01575 | 34688168 | Curr Opin Pharmacol | Non-alcoholic fatty liver disease: Current therapeutic options. | 2021 | Details |
| A01843 | 34593018 | BMC Pharmacol Toxicol | Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. | 2021 | Details |
| A01937 | 34558835 | Hepatol Commun | Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. | 2021 | Details |
| A02124 | 34497708 | Ther Adv Endocrinol Metab | Therapeutic approaches for non-alcoholic steatohepatitis. | 2021 | Details |
| A02209 | 34459761 | Wiad Lek | ASSOCIATION ANALYSIS OF PIOGLITAZONE EFFECTIVENESS IN TREATMENT OF NAFLD PATIENTS WITH OBESITY AND PPARG RS1801282 (PRO12ALA) GENOTYPE. | 2021 | Details |
| A02287 | 34435378 | Aliment Pharmacol Ther | Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. | 2021 | Details |
| A02330 | 34416040 | Aliment Pharmacol Ther | Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. | 2021 | Details |
| A02349 | 34406410 | J Clin Endocrinol Metab | The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. | 2022 | Details |
| A02399 | 34386935 | Hepatol Int | First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. | 2021 | Details |
| A02496 | 34352720 | Diabetes Metab Syndr | Meta-analysis of trials in non-alcoholic fatty liver disease with therapeutic interventions for metabolic syndrome. | 2021 | Details |
| A02557 | 34328687 | Liver Int | Zonation in NASH - A key paradigm for understanding pathophysiology and clinical outcomes. | 2021 | Details |
| A02579 | 34324263 | Diabetes Obes Metab | Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. | 2021 | Details |
| A02609 | 34311022 | Diabetes Res Clin Pract | Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. | 2021 | Details |
| A02850 | 34219361 | Liver Int | PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. | 2021 | Details |
| A02937 | 34191493 | Anal Chem | Exploring the Changes of Peroxisomal Polarity in the Liver of Mice with Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A02955 | 34185201 | Inflammopharmacology | Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD. | 2021 | Details |
| A03040 | 34155798 | Liver Int | Non-alcoholic fatty liver disease in type 2 diabetes - A specific entity? | 2021 | Details |
| A03067 | 34144391 | Redox Biol | Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules. | 2021 | Details |
| A03126 | 34119888 | Biomaterials | A scalable and sensitive steatosis chip with long-term perfusion of in situ differentiated HepaRG organoids. | 2021 | Details |
| A03289 | 34059612 | Curr Opin Cardiol | Update on cardiovascular risk in nonalcoholic fatty liver disease. | 2021 | Details |
| A03367 | 34027269 | Hepatol Commun | Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. | 2021 | Details |
| A03431 | 34002333 | Diabetes Ther | Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. | 2021 | Details |
| A03451 | 33995271 | Front Endocrinol (Lausanne) | Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. | 2021 | Details |
| A03840 | 33852508 | Eur J Gastroenterol Hepatol | The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. | 2022 | Details |
| A03861 | 33841337 | Front Endocrinol (Lausanne) | Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. | 2021 | Details |
| A03995 | 33798599 | Eur J Pharmacol | Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH. | 2021 | Details |
| A04130 | 33746449 | J Clin Exp Hepatol | What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? | 2020 | Details |
| A04349 | 33652942 | Int J Mol Sci | Treatments for NAFLD: State of Art. | 2021 | Details |
| A04466 | 33604254 | J Clin Transl Hepatol | Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail. | 2020 | Details |
| A04509 | 33593749 | BMJ Open Diabetes Res Care | Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. | 2021 | Details |
| A04530 | 33586120 | Diabetes Ther | Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. | 2021 | Details |
| A04814 | 33497019 | Liver Int | Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. | 2021 | Details |
| A04896 | 33461969 | BMJ | Management of non-alcoholic fatty liver disease. | 2021 | Details |
| A05040 | 33397443 | Biol Sex Differ | Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism. | 2021 | Details |
| A05041 | 33397230 | Curr Pharm Des | Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. | 2021 | Details |
| A05080 | 33385317 | J Dig Dis | Efficacy and safety of drugs for nonalcoholic steatohepatitis. | 2021 | Details |
| A05119 | 33368954 | Diabetes Obes Metab | Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. | 2021 | Details |
| A05137 | 33359401 | Mol Metab | Insulin resistance is mechanistically linked to hepatic mitochondrial remodeling in non-alcoholic fatty liver disease. | 2020 | Details |
| A05758 | 33131199 | J Diabetes Investig | Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. | 2020 | Details |
| A05793 | 33115209 | Diabetes Metab J | Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. | 2020 | Details |
| A05807 | 33113501 | Phytomedicine | Modulation of IR as a therapeutic target to prevent NASH using NRF from Diceratella elliptica (DC.) jonsell. Strong Nrf2 and leptin inducer as well as NF-kB inhibitor. | 2020 | Details |
| A06074 | 33015726 | Curr Diab Rep | Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06220 | 32963510 | PPAR Res | Diet Modifies Pioglitazone's Influence on Hepatic PPARγ-Regulated Mitochondrial Gene Expression. | 2020 | Details |
| A06367 | 32912770 | Dig Liver Dis | Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map. | 2020 | Details |
| A06658 | 32791578 | Clin Mol Hepatol | Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. | 2020 | Details |
| A06708 | 32774420 | Evid Based Complement Alternat Med | Anti-inflammatory Mechanism of Ruzu Bitters on Diet-Induced Nonalcoholic Fatty Liver Disease in Male Wistar Rats. | 2020 | Details |
| A06984 | 32673798 | Mol Metab | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. | 2020 | Details |
| A07060 | 32638417 | Aliment Pharmacol Ther | Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. | 2020 | Details |
| A07125 | 32613381 | Cell Biol Toxicol | Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. | 2020 | Details |
| A07131 | 32608271 | Arch Physiol Biochem | Improvement of thiol groups and total antioxidant capacity in patients with non-alcoholic fatty liver after treatment with pioglitazone. | 2020 | Details |
| A07141 | 32605253 | Cancers (Basel) | Current and Future Treatments in the Fight Against Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A07368 | 32524096 | Hawaii J Health Soc Welf | Nonalcoholic Fatty Liver Disease: An Important Consideration for Primary Care Providers in Hawai'i. | 2020 | Details |
| A07385 | 32518275 | Sci Rep | The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A07423 | 32506513 | J Gastroenterol Hepatol | Use of metabolic syndrome severity to assess treatment with vitamin E and pioglitazone for non-alcoholic steatohepatitis. | 2020 | Details |
| A07483 | 32477107 | Front Pharmacol | Gut-Derived Serotonin Contributes to the Progression of Non-Alcoholic Steatohepatitis via the Liver HTR2A/PPARγ2 Pathway. | 2020 | Details |
| A07609 | 32424494 | Adv Exp Med Biol | Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. | 2021 | Details |
| A07648 | 32409850 | Internist (Berl) | [New pharmacological treatment options for nonalcoholic fatty liver disease]. | 2020 | Details |
| A07769 | 32360434 | J Hepatol | Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆. | 2020 | Details |
| A07866 | 32329963 | J Diabetes Investig | Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. | 2020 | Details |
| A08128 | 32237916 | Expert Opin Pharmacother | Current and new pharmacotherapy options for non-alcoholic steatohepatitis. | 2020 | Details |
| A08288 | 32168769 | Int J Mol Sci | Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A08327 | 32151660 | Metabolism | Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08431 | 32113823 | Clin Res Hepatol Gastroenterol | Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. | 2020 | Details |
| A08505 | 32083445 | Horm Mol Biol Clin Investig | Hepatoprotective effects of Shilajit on high fat-diet induced non-alcoholic fatty liver disease (NAFLD) in rats. | 2020 | Details |
| A08516 | 32077613 | Liver Int | A diabetologist's perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions. | 2020 | Details |
| A08701 | 32017891 | Am J Med | Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? | 2020 | Details |
| A08856 | 31963648 | J Clin Med | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. | 2020 | Details |
| A08869 | 31956725 | Contemp Clin Trials Commun | Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). | 2019 | Details |
| A08963 | 31923578 | Diabetes Metab | Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. | 2020 | Details |
| A09047 | 31889754 | J Clin Exp Hepatol | Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09096 | 31877771 | Cells | Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. | 2019 | Details |
| A09226 | 31829750 | Expert Opin Investig Drugs | Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. | 2019 | Details |
| A09343 | 31783920 | Syst Rev | Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. | 2019 | Details |
| A09349 | 31782258 | Physiol Rep | SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model. | 2019 | Details |
| A09620 | 31672448 | Metabolism | Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! | 2019 | Details |
| A09715 | 31635468 | Vnitr Lek | Non-Alcoholic Fatty Liver Disease. | 2019 | Details |
| A09758 | 31622581 | Am J Med | Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09774 | 31614690 | Int J Mol Sci | Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. | 2019 | Details |
| A09857 | 31589891 | J Hepatol | Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. | 2019 | Details |
| A09924 | 31558860 | World J Gastroenterol | Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. | 2019 | Details |
| A09955 | 31543686 | World J Gastroenterol | Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. | 2019 | Details |
| A10238 | 31418344 | Curr Vasc Pharmacol | What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? | 2019 | Details |
| A10342 | 31382287 | Ann Intern Med | How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. | 2019 | Details |
| A10401 | 31353974 | Expert Rev Gastroenterol Hepatol | Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. | 2019 | Details |
| A10452 | 31332029 | Diabetes Care | Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. | 2019 | Details |
| A10508 | 31308716 | Diabetes Metab Syndr Obes | SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions. | 2019 | Details |